BioSight
Companies
Milestone Pharmaceuticals Inc. logo

MIST

NASDAQMONTREAL, A8
Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals develops intravenous and intranasal drug formulations, with a primary focus on etripamil for treating paroxysmal supraventricular tachycardia (PSVT). CARDAMYST (etripamil nasal spray) has been commercialized for converting acute symptomatic PSVT episodes to normal heart rhythm in adults, and the company is conducting Phase 3 clinical trials for additional indications. Milestone is in the late-stage clinical development phase with at least one marketed product.

Price history not yet available for MIST.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar